Idera Pharmaceuticals, Inc.

NASDAQ:IDRA  
1.07
0.00 (0.00%)
5:21:30 PM EDT: $1.09 +0.02 (+1.87%)
Products, Regulatory, Earnings Announcements

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial Of Tilsotolimod + Ipilimumab In Anti-PD-1 Refractory Advanced Melanoma

Published: 03/18/2021 21:42 GMT
Idera Pharmaceuticals, Inc. (IDRA) - Idera Pharmaceuticals Announces Results From Illuminate-301 Trial of Tilsotolimod + Ipilimumab in Anti-pd-1 Refractory Advanced Melanoma.
Idera Pharmaceuticals - Plans Its Illuminate-206 Phase 2 Study of Tilsotolimod in Combination With Ipilimumab and Nivolumab in Patients With Mss-crc.
Idera Pharmaceuticals - Registration Trial of Tilsotolimod Did Not Meet Its Primary Endpoint of Objective Response Rate.
Idera Pharmaceuticals Inc - Although Primary Endpoint of Orr Was Not Met, If Study Continues and Reaches a Positive Os Outcome.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.18

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.